Session Sponsor

Session Overview

Stem cells have the ability to differentiate into more specialised cells and proliferate by mitosis when cultured under certain physiological conditions. The use and development of human induced pluripotent stem cells (hiPSCs) has many distinct benefits to cellular and molecular human disease research (and toxicity testing) and consequently excellent animal replacement potential for many different research areas.

Session Chair: Dr Pascale V Guillot

Senior Lecturer in Fetal and Maternal Health (University College London)

Dr Pascale V Guillot is a stem cell biologist at University College London, where she was first to reprogram human cells back to functional pluripotency using chemicals alone, without ectopic expression of transcription factors.  After a PhD in Paris, France, and a first postdoctoral training with Dr Mary Lyon at Harwell Laboratories (Didcot, UK) to develop her expertise in gene mapping, she went to Harvard Medical School (Boston MA, US) and the National Institute of Health (Washington DC, US). Back in the UK, she is using induced mesenchymal stem cells, derived from induced pluripotent stem cells, to delineate the molecular mechanisms by which stem cell mediate their tissue repair capacity.




Recent Publications

Hawkins, K., Moschidou, D., Faccenda, D., Wruck, W., Martin-Trujillo, A., Hau, K. -. L., . . . Guillot, P. (2017). Human amniocytes are receptive to chemically-induced reprogramming to pluripotency. Molecular Therapy, 25 (2), 427-442. doi:10.1016/j.ymthe.2016.11.014

Hau, K. -. L., Ranzoni, A. M., Vlahova, F., Hawkins, K., De Coppi, P., David, A. L., & Guillot, P. V. (2017). TGFβ-induced osteogenic potential of human amniotic fluid stem cells via CD73-generated adenosine production. Sci Rep, 7 (1), 6601. doi:10.1038/s41598-017-06780-1

Ranzoni, A. M., Corcelli, M., Hau, K. L., Kerns, J. G., Vanleene, M., Shefelbine, S., . . . Guillot, P. V. (2016). Counteracting bone fragility with human amniotic mesenchymal stem cells. Scientific Reports, 6, 39656. doi:10.1038/srep39656

Moschidou, D., Corcelli, M., Hau, K. -. L., Ekwalla, V. J., Behmoaras, J. V., De Coppi, P., . . . Guillot, P. V. (2016). Human Chorionic Stem Cells: Podocyte Differentiation and Potential for the Treatment of Alport Syndrome. STEM CELLS AND DEVELOPMENT, 25 (5), 395-404. doi:10.1089/scd.2015.0305

Guillot, P. V. (2016). Induced pluripotent stem (iPS) cells from human fetal stem cells. BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 31, 112-120. doi:10.1016/j.bpobgyn.2015.08.007

What papers are we looking for?

We are looking for a wide variety of papers on this topic to provide an academic and industry perspective.

Topics of interest include: use of iPS cells for disease modelling, developing organs on chip, direct lineage reprogramming and testing drug safety and efficacy using iPS cells.

Interested in presenting?

Get in touch via the below form and we will get back to you as soon as possible.

The Presenters


Dr Carl Sheridan

Senior Lecturer in Ocular Cell Transplantation

University of Liverpool

Seeing is believing in tissue engineering and cell transplants in the eye

View Abstract

Giorgia Salvagiotto

Senior Field Application Scientist

Cellular Dynamics International

Advancing drug discovery and therapeutic programs with physiologically relevant human iPSC-derived cellular systems

View Abstract

Nick Allen


Cardiff University

IPSC models of neurodegenerative disease

View Abstract



Dr Jamuna Selvakumaran

Postdoctoral Research Fellow

Royal Holloway University of London

Improved in vitro models of the human blood-brain barrier (BBB) using endothelial cells derived from induced pluripotent stem cells (iPSCs) for testing CNS therapeutics

View Abstract

Dr Panagiota Moutsatsou

Postdoctoral Research Associate

Aston University

H2020 Autostem: Development of a fully automated platform for the manufacture of adults stem cells for cell therapies

View Abstract

To be confirmed




Title Sponsor